Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Neurodegeneration biomarkers and longitudinal studies

Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.

Yi-He Chen; Rong-Rong Lin; Hui-Feng Huang; Yan-Yan Xue; Qing-Qing Tao

Originally published in Frontiers in aging neuroscience · 2022-06-30

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Purpose Biomarkers used for predicting longitudinal cognitive change in Alzheimer's disease (AD) continuum are still elusive. Tau pathology, neuroinflammation, and neurodegeneration are the leading candidate predictors. We aimed to determine these three aspects of biomarkers in cerebrospinal fluid (CSF) and plasma to predict longitudinal cognition status using Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Patients and methods A total of 430 subjects including, 96 cognitive normal (CN) with amyloid β (Aβ)-negative, 54 CN with Aβ-positive, 195 mild cognitive impairment (MCI) with Aβ-positive, and 85 AD with amyloid-positive (Aβ-positive are identified by CSF Aβ42/Aβ40 Results Baseline CSF Aβ42/Aβ40 ratio was decreased in MCI and AD compared to CN, while CSF p-tau181 and t-tau increased. Baseline CSF sTREM2 and PGRN did not show any differences in MCI and AD compared to CN. Baseline brain volumes (including the hippocampal, entorhinal, middle temporal lobe, and whole-brain) decreased in MCI and AD groups.

Discussion

AD is a devastating disease that brings a heavy burden to society and families. Reliable prognostic and outcome measures are of great importance in clinical practice and clinical trials. However, biomarkers used for predicting longitudinal cognitive change in the AD continuum are still unknown. Tau pathology, neuroinflammation, and neurodegeneration are the leading potential predictors for longitudinal cognitive change.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?